Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2002

View Archived Issues

Verapamil is effective in the treatment of Peyronie's disease

ABI-007, a new cremophor-free nanoparticle formulation of paclitaxel

Kansas State University researchers identify nucleoside transport inhibitor TT-24

IL-10 gene therapy prevents recurrence of autoimmune diabetes after islet transplantation

CD45RB MAb prolongs allograft survival in mice

Bimosiamose prolongs rat kidney allograft survival by reducing intragraft cytokine production

Inhibition of COX-2 with NS-398 prolongs allogeneic cardiac graft survival

Takeda presents SAR studies for TAK-013 and TAK-810

UCB-35440 discussed at recent ACS meeting

Cyclic beta-amino acids with VLA-4 antagonist activity presented at ACS

Milnacipran to be studied in depressed mood associated with chronic pain conditions

Pfizer submits IND for bone growth product

Sankyo files supplemental NDA for Benicar HCT

Lantus launch in U.K.

P-54 may reduce steroid dependency in patients with mild inflammatory bowel disease

Xigris approved in E.U.

Orion files NDA for triple combination therapy for Parkinson's disease

A-317920 shows potential for Alzheimer's disease and ADHD

Bayer claims compounds with antitumor activity

Orexin receptor antagonists described by Actelion

Antifungal compounds that inhibit CIV1 activity

Telomerase-inhibiting compounds described by Geron and Kyowa Hakko

New mGLUR1 antagonists claimed by Roche for neurological disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...